Hycamtin Shortage: What Providers and Prescribers Need to Know in 2026

For oncologists, hematologist-oncologists, and other providers prescribing topotecan (Hycamtin), access challenges are not theoretical — they directly affect patient care timelines and outcomes. This guide covers the current state of Hycamtin availability, practical sourcing strategies, dose management considerations, and evidence-based alternatives for providers managing patients who rely on this drug.

Current Supply Status (2026)

As of early 2026, topotecan is not listed as an active shortage drug by the FDA. Generic topotecan IV (4 mg vials) is available from multiple ANDA-approved manufacturers, and hospital group purchasing organizations (GPOs) can generally source it through their distributor networks. However, practice-level access issues persist for several reasons:

The oral capsule formulation (Hycamtin 0.25 mg and 1 mg) has limited specialty pharmacy availability and may require coordination through specific network pharmacies

Prior authorization and specialty pharmacy network requirements create patient access delays independent of actual drug supply

Localized distributor-level stock-outs can occur even when national supply is adequate

Historical Context: The 2017 Hycamtin Shortage

Providers should be aware that Novartis previously experienced a shortage of Hycamtin oral capsules in both the 0.25 mg and 1 mg strengths, first reported by ASHP in March 2017. The shortage was resolved in October 2017 with new NDC numbers. No manufacturer reason was provided. This history underscores the vulnerability of single-source oral specialty formulations and the importance of proactive sourcing and contingency planning.

FDA-Approved Indications for Topotecan: A Clinical Review

Topotecan carries three FDA-approved indications:

Metastatic ovarian cancer — single agent after disease progression on or after initial or subsequent chemotherapy (IV, 1.5 mg/m² x 5 days q21d)

SCLC — platinum-sensitive relapse — progressed ≥60 days after first-line chemotherapy; both IV (1.5 mg/m² x 5 days q21d) and oral (2.3 mg/m²/day x 5 days q21d) formulations approved

Cervical cancer — Stage IV-B, recurrent or persistent, not amenable to curative treatment; topotecan 0.75 mg/m² days 1–3 in combination with cisplatin 50 mg/m² day 1, q21d

Key Safety Considerations and Monitoring Requirements

Topotecan carries a boxed warning for severe myelosuppression. Key requirements include:

Baseline ANC ≥1,500/mm³ and platelets ≥100,000/mm³ required before first cycle

Monitor CBC frequently; hold subsequent cycles until ANC >1,000/mm³, platelets >100,000/mm³, and Hgb ≥9 g/dL

Grade 4 neutropenia occurs in 78% of IV patients; febrile neutropenia in 5%; sepsis in 4%

G-CSF use permitted but should not begin before Day 6 of each cycle (24 hours after last dose)

Neutropenic enterocolitis (typhlitis): consider in patients with fever, neutropenia, and abdominal pain

ILD: permanently discontinue if confirmed

Renal impairment dose reduction: 0.75 mg/m²/day for CrCl 20–39 mL/min

Therapeutic Alternatives When Topotecan Is Unavailable

When topotecan is genuinely inaccessible, providers should consider the following evidence-based alternatives by indication:

For SCLC (Relapsed/Refractory)

Lurbinectedin (Zepzelca) — FDA accelerated approval 2020 for mSCLC post-platinum progression; ORR ~35%; 3.2 mg/m² IV q21d

Platinum rechallenge (carboplatin/etoposide) — preferred for platinum-sensitive relapse (>90 days from end of first-line); NCCN preferred regimen

Irinotecan — another topo I inhibitor; NCCN-listed option; some cross-resistance with topotecan

CAV (cyclophosphamide, doxorubicin, vincristine) — historical standard pre-topotecan; similar efficacy but worse QoL vs. topotecan in RCTs

For Ovarian Cancer

NCCN guidelines for recurrent ovarian cancer list numerous options depending on platinum sensitivity, prior therapy, and molecular status: gemcitabine, paclitaxel, liposomal doxorubicin (Doxil), olaparib or other PARP inhibitors (for BRCA-mutated), bevacizumab, and others. Consult the most current NCCN guidelines for evidence-based sequencing.

Practical Sourcing Strategies for Practices

When topotecan supply is tight at your standard distributor, consider these approaches:

Work with your GPO (e.g., Vizient, Premier, Intalere) to identify alternate distributors or manufacturers

Contact your state's oncology society or hospital pharmacy association for shortage mitigation resources

Use medfinder for patients who need the oral formulation — it calls pharmacies on the patient's behalf to identify which specialty pharmacies have it in stock

For provider-facing tools to help your patients access topotecan and other difficult-to-find medications, visit medfinder for providers.

See also our companion article: How to Help Your Patients Find Hycamtin in Stock: A Provider's Guide.